Aberrant DNA methylation in contrast with mutations

Cancer Science

Volumn 101, Issue 2, 2010, Pages 300-305

  Ushijima, Toshikazu ^a   Asada, Kiyoshi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA; HISTONE H3; RNA POLYMERASE II; TOBACCO SMOKE;

AGING; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CHRONIC INFLAMMATION; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC RISK; HELICOBACTER PYLORI; HUMAN; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; REVIEW; SOMATIC MUTATION; STOMACH CANCER; ULCERATIVE COLITIS;

ANIMALS; CPG ISLANDS; DNA METHYLATION; HUMANS; MUTATION; NEOPLASMS;

EID: 75649094543     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01434.x     Document Type: Review

References (73)

1. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007, 128:683-92.
2. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358:1148-59.
3. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005, 5:223-31.
4. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92.
5. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004, 4:143-53.
6. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature 1998, 395:89-93.
7. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300:455.
8. Yamada Y, Jackson-Grusby L, Linhart H. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Acad Sci U S A 2005, 102:13.
9. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007, 128:707-19.
10. Lin JC, Jeong S, Liang G. Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell 2007, 12:432-44.
11. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 1993, 8:1063-7.
12. Ushijima T, Sasako M. Focus on gastric cancer. Cancer Cell 2004, 5:121-5.
13. Ushijima T, Morimura K, Hosoya Y. Establishment of methylation-sensitive-representational difference analysis and isolation of hypo- and hypermethylated genomic fragments in mouse liver tumors. Proc Natl Acad Sci U S A 1997, 94:2284-9.
14. Gonzalgo ML, Liang G, Spruck CH, Zingg JM, Rideout WM, Jones PA. Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. Cancer Res 1997, 57:594-9.
15. Huang TH, Laux DE, Hamlin BC, Tran P, Tran H, Lubahn DB. Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique. Cancer Res 1997, 57:1030-4.
16. Toyota M, Ho C, Ahuja N. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999, 59:2307-12.
17. Greenman C, Stephens P, Smith R. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-8.
18. Wood LD, Parsons DW, Jones S. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-13.
19. Gal-Yam EN, Egger G, Iniguez L. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci U S A 2008, 105:12.
20. Weber M, Hellmann I, Stadler MB. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007, 39:457-66.
21. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999, 21:163-7.
22. Ball MP, Li JB, Gao Y. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 2009, 27:361-8.
23. Yamashita S, Hosoya K, Gyobu K, Takeshima H, Ushijima T. Development of a novel output value for quantitative assessment in methylated DNA immunoprecipitation-CpG island microarray analysis. DNA Res 2009, 16:275-86.
24. Hellman A, Chess A. Gene body-specific methylation on the active X chromosome. Science 2007, 315:1141-3.
25. Rauch TA, Wu X, Zhong X, Riggs AD, Pfeifer GP. A human B cell methylome at 100-base pair resolution. Proc Natl Acad Sci U S A 2009, 106:671-8.
26. Chan TA, Glockner S, Yi JM. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med 2008, 5:e114.
27. Keshet I, Schlesinger Y, Farkash S. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet 2006, 38:149-53.
28. Hayashi H, Nagae G, Tsutsumi S. High-resolution mapping of DNA methylation in human genome using oligonucleotide tiling array. Hum Genet 2007, 120:701-11.
29. Gao W, Kondo Y, Shen L. Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis 2008, 29:1901-10.
30. Rauch TA, Zhong X, Wu X. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci U S A 2008, 105:252-7.
31. Pelizzola M, Koga Y, Urban AE. MEDME: an experimental and analytical methodology for the estimation of DNA methylation levels based on microarray derived MeDIP-enrichment. Genome Res 2008, 18:1652-9.
32. Down TA, Rakyan VK, Turner DJ. A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. Nat Biotechnol 2008, 26:779-85.
33. Straussman R, Nejman D, Roberts D. Developmental programming of CpG island methylation profiles in the human genome. Nat Struct Mol Biol 2009, 16:564-71.
34. Takeshima H, Yamashita S, Shimazu T, Niwa T, Ushijima T. The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. Genome Res 2009, 19:1974-82.
35. Markl ID, Cheng J, Liang G, Shibata D, Laird PW, Jones PA. Global and gene-specific epigenetic patterns in human bladder cancer genomes are relatively stable in vivo and in vitro over time. Cancer Res 2001, 61:5875-84.
36. Smiraglia DJ, Rush LJ, Fruhwald MC. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet 2001, 10:1413-9.
37. Costello JF, Fruhwald MC, Smiraglia DJ. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000, 24:132-8.
38. Weber M, Davies JJ, Wittig D. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005, 37:853-62.
39. Enomoto S, Maekita T, Tsukamoto T. Lack of association between CpG island methylator phenotype in human gastric cancers and methylation in their background non-cancerous gastric mucosae. Cancer Sci 2007, 98:1853-61.
40. Oka D, Yamashita S, Tomioka T. The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of esophageal cancers. Cancer 2009, 115:3412-26.
41. Kaneda A, Wakazono K, Tsukamoto T. Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. Cancer Res 2004, 64:6410-5.
42. Kohler SW, Provost GS, Fieck A. Spectra of spontaneous and mutagen-induced mutations in the lacI gene in transgenic mice. Proc Natl Acad Sci U S A 1991, 88:7958-62.
43. Tao KS, Urlando C, Heddle JA. Comparison of somatic mutation in a transgenic versus host locus. Proc Natl Acad Sci U S A 1993, 90:10.
44. Nagao M, Ochiai M, Okochi E, Ushijima T, Sugimura T. LacI transgenic animal study: relationships among DNA-adduct levels, mutant frequencies and cancer incidences. Mutat Res 2001, 477:119-24.
45. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994, 7:536-40.
46. Maekita T, Nakazawa K, Mihara M. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006, 12:989-95.
47. Nakajima T, Maekita T, Oda I. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomarkers Prev 2006, 15:2317-21.
48. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis--A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 2000, 32:970-9.
49. Shen L, Kondo Y, Rosner GL. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005, 97:1330-8.
50. Ishii T, Murakami J, Notohara K. Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut 2007, 56:13-9.
51. Arai E, Kanai Y, Ushijima S, Fujimoto H, Mukai K, Hirohashi S. Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. Int J Cancer 2006, 119:288-96.
52. Ushijima T. Epigenetic field for cancerization. J Biochem Mol Biol 2007, 40:142-50.
53. Suzuki H, Watkins DN, Jair KW. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004, 36:417-22.
54. Lichtenstein P, Holm NV, Verkasalo PK. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343:78-85.
55. Ushijima T, Okochi-Takada E. Aberrant methylations in cancer cells: Where do they come from? Cancer Sci 2005, 96:206-11.
56. Morley AA, Turner DR. The contribution of exogenous and endogenous mutagens to in vivo mutations. Mutat Res 1999, 428:11-5.
57. Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M, Porschen R. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res 1998, 58:3942-5.
58. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001, 61:3573-7.
59. Eads CA, Lord RV, Kurumboor SK. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000, 60:5021-6.
60. Okochi-Takada E, Ichimura S, Kaneda A, Sugimura T, Ushijima T. Establishment of a detection system for demethylating agents using an endogenous promoter CpG island. Mutat Res 2004, 568:187-94.
61. Loeb LA. A mutator phenotype in cancer. Cancer Res 2001, 61:3230-9.
62. Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG, Harris CC. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol 1999, 187:8-18.
63. Nakajima T, Yamashita S, Maekita T, Niwa T, Nakazawa K, Ushijima T. The presence of a methylation fingerprint of Helicobacter pylori infection in human gastric mucosae. Int J Cancer 2009, 124:905-10.
64. de Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol Cell Biol 2004, 24:4781-90.
65. Song JZ, Stirzaker C, Harrison J, Melki JR, Clark SJ. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 2002, 21:1048-61.
66. Ohm JE, McGarvey KM, Yu X. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007, 39:237-42.
67. Schlesinger Y, Straussman R, Keshet I. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007, 39:232-6.
68. Widschwendter M, Fiegl H, Egle D. Epigenetic stem cell signature in cancer. Nat Genet 2007, 39:157-8.
69. McGarvey KM, Van Neste L, Cope L. Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. Cancer Res 2008, 68:5753-9.
70. Gan Q, Yoshida T, McDonald OG, Owens GK. Concise review: epigenetic mechanisms contribute to pluripotency and cell lineage determination of embryonic stem cells. Stem Cells 2007, 25:2-9.
71. Meissner A, Mikkelsen TS, Gu H. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008, 454:766-70.
72. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980, 20:85-93.
73. Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res 2009, 15:3938-46.